BMY Bristol-Myers Squibb Company Common Stock
O Bristol-Myers Squibb Company Common Stock Przegląd firmy z Wikipedii
Bristol-Myers Squibb – firma biofarmaceutyczna powstała w 1989 z połączenia Bristol-Myers Company oraz Squibb Corporation. Spółka ma siedzibę główną w Nowym Jorku.
Czytaj więcej
Bristol-Myers Squibb (zwyczajowo BMS) – firma biofarmaceutyczna powstała w 1989 z połączenia Bristol-Myers Company (utworzonej w 1887 przez Williama McLarena Bristola i Johna Ripleya Myersa w Clinton) oraz Squibb Corporation (założonej w 1858 przez Edwarda Robinsona Squibba). Spółka ma siedzibę główną w Nowym Jorku.
Firma produkuje między innymi: Plavix (klopidogrel), Avapro (irbesartan) (we współpracy z Sanofi-Aventis), Tequin (gatifloksacyna), Sustiva (efawirenz), Taxol (paklitaksel), Abilify (arypiprazol), Erbitux (cetuksymab), Baraclude (entekawir), Orencia (abatacept), Ixempra (iksabepilon), Sprycel (dasatinib), Yervoy (ipilimumab), Averroes (apiksaban), Opdivo (niwolumab), Atripla, Nulojix (belatacept) .
Od 2002 firma wprowadziła na rynek osiem nowych leków.
W 2003 firma zorganizowała imprezę kolarską Tour of Hope, w której oprócz lekarzy i naukowców brali udział wyleczeni z raka, w tym Lance Armstrong. Impreza miała za zadanie promować ważność oraz konieczność prowadzenia badań klinicznych dla rozwoju nowych terapii raka.
W Polsce przedstawicielstwo obu firm powstało w latach 60. XX wieku. W Polsce znajduje się również centrala badań klinicznych dla regionu obejmującego Polskę, Rosję, Czechy, Węgry, Rumunię, Turcję i Ukrainę (badania tam prowadzone stanowią 18 proc. wszystkich badań realizowanych w firmie).
Firma w 2002 i 2007 zdobyła wyróżnienie Najlepsza Firma – Przyjaciel Ruchu Hospicyjnego. W 2006 została odznaczona Czerwoną Kokardką za wkład w opiekę nad pacjentami z AIDS (wyróżnienie Krajowego Centrum ds. AIDS). W 2010 zdobyła pierwsze miejsce w rankingu Najlepsze Miejsca Pracy Polska 2010 a w 2012 trzecie miejsce i trzydzieste ósme miejsce w rankingu Najlepszych Miejsc Pracy w Europie. 16 lat z rzędu firma znajduje się na liście 100 najbardziej przyjaznych firm w USA dla pracujących matek.
W związku z nową strategią od 2007 roku firma zaczęła przejmować małe firmy biotechnologiczne (m.in. ZymoGenetics, Kosan Biosciences, Medarex, Adnexus Therapeutics) w celu uzyskania dostępu do nowoczesnych leków we wczesnych fazach badań.
## Leki w fazie przedrejestracyjnych badań klinicznych
BMS-936558
Urelumab
Necitumumab
Źródło: Wikipedia, CC BY-SA 4.0 · Zobacz w Wikipedii ↗
BMY Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
BMY Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
| Data ex-dywidendy | Kwota |
|---|---|
| 2 lipca 2026 | $0,6300 |
| 2 kwietnia 2026 | $0,6300 |
| 2 stycznia 2026 | $0,6300 |
| 3 października 2025 | $0,6200 |
| 3 lipca 2025 | $0,6200 |
| 4 kwietnia 2025 | $0,6200 |
| 3 stycznia 2025 | $0,6200 |
| 4 października 2024 | $0,6000 |
| 5 lipca 2024 | $0,6000 |
| 4 kwietnia 2024 | $0,6000 |
| 4 stycznia 2024 | $0,6000 |
| 5 października 2023 | $0,5700 |
| 6 lipca 2023 | $0,5700 |
| 6 kwietnia 2023 | $0,5700 |
| 5 stycznia 2023 | $0,5700 |
| 6 października 2022 | $0,5400 |
| 30 czerwca 2022 | $0,5400 |
| 31 marca 2022 | $0,5400 |
| 6 stycznia 2022 | $0,5400 |
| 30 września 2021 | $0,4900 |
BMY Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
- Mocne kupno 6 17,1%
- Kup 8 22,9%
- Trzymaj 19 54,3%
- Sprzedaj 2 5,7%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
24 analityków · 2026-08-17Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $2.04 | $1.60 | 0.44% |
| 31 marca 2026 | $1.58 | $1.43 | 0.15% |
| 31 grudnia 2025 | $1.26 | $1.13 | 0.13% |
| 30 września 2025 | $1.63 | $1.52 | 0.11% |
| 30 czerwca 2025 | $1.46 | $1.08 | 0.38% |
| 31 marca 2025 | $1.80 | $1.51 | 0.29% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | |
| Gross Profit | · | · | · | · | · | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | |
| R&D Expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | |
| Interest Expense | · | · | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | |
| Interest Income | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | |
| Other Non-op | $-674M | $-893M | $1.16B | $-576M | $720M | $2.31B | $-938M | $854M | $1.69B | $1.45B | $187M | $-210M | |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | |
| Income Tax | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B | $446M | $352M | |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | |
| Shares (Basic) | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 | 2,221,000,000 | 2,258,000,000 | 1,705,000,000 | 1,633,000,000 | 1,645,000,000 | 1,671,000,000 | 1,667,000,000 | 1,657,000,000 | |
| Shares (Diluted) | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 | 2,245,000,000 | 2,258,000,000 | 1,712,000,000 | 1,637,000,000 | 1,652,000,000 | 1,680,000,000 | 1,679,000,000 | 1,670,000,000 | |
| EBITDA | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M |
Bilans 31
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B | $2.38B | $5.57B | |
| Short-term Investments | · | · | · | $130M | $2.99B | $1.28B | $3.05B | $1.85B | $1.39B | $2.11B | $1.89B | $1.86B | |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B | $7.22B | $6.48B | $4.64B | $4.35B | $3.77B | $2.95B | $2.10B | |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B | $4.29B | $1.20B | $1.17B | $1.24B | $1.22B | $1.56B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | $576M | $570M | $625M | $470M | |
| Other Current Assets | $4.61B | $5.62B | $5.91B | $5.79B | $4.83B | $3.79B | $1.98B | $2.02B | $576M | $570M | $625M | $470M | |
| Current Assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B | $10.41B | $14.61B | |
| PP&E (Net) | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B | $5.89B | $6.25B | $5.03B | $5.00B | $4.98B | $4.41B | $4.42B | |
| PP&E (Gross) | $12.84B | $12.09B | $11.45B | $10.42B | $10.08B | $9.47B | $10.21B | $8.85B | $8.99B | $9.17B | $8.63B | $9.07B | |
| Accum. Depreciation | $5.29B | $4.95B | $4.80B | $4.16B | $4.03B | $3.58B | $3.96B | $3.82B | $3.99B | $4.19B | $4.22B | $4.65B | |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B | $22.49B | $6.54B | $6.86B | $6.88B | $6.88B | $7.03B | |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B | $53.24B | $63.97B | $1.09B | $1.21B | $1.39B | $1.42B | $1.75B | |
| Other Non-current Assets | $6.47B | $6.11B | $5.37B | $4.94B | $5.54B | $7.02B | $6.60B | $2.02B | $1.53B | $1.05B | $1.12B | $621M | |
| Total Assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B | |
| Accounts Payable | $3.58B | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B | $2.44B | $1.89B | $2.25B | $1.66B | $1.56B | $2.49B | |
| Accrued Liabilities | · | · | · | · | · | · | · | $6.49B | $6.01B | $5.27B | $4.74B | $2.46B | |
| Short-term Debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987M | $109M | $139M | $590M | |
| Current Liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B | $18.30B | $10.65B | $9.56B | $8.84B | $8.02B | $8.46B | |
| Capital Leases | $1.83B | $1.37B | $1.53B | $1.26B | $874M | $833M | $672M | $0 | · | · | · | · | |
| Deferred Tax | $222M | $369M | $338M | $2.17B | $4.50B | $5.41B | $6.45B | $19M | $45M | $47M | $31M | $60M | |
| Other Non-current Liabilities | $5.04B | $4.47B | $6.42B | $6.59B | $7.33B | $7.78B | $10.10B | $4.54B | $1.16B | $1.28B | $1.43B | $618M | |
| Total Liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B | $17.32B | $18.77B | |
| Long-term Debt | $44.83B | $49.43B | $39.53B | $38.95B | $44.37B | $50.34B | $46.15B | $6.89B | $6.97B | $6.46B | · | · | |
| Total Debt | $47.09B | $51.48B | $42.65B | $43.22B | $49.32B | $52.68B | $49.50B | $8.60B | $7.49B | $7.46B | $6.69B | $7.83B | |
| Common Stock | · | · | · | $292M | $292M | $292M | $292M | $221M | $221M | $221M | $221M | $221M | |
| Paid-in Capital | $46.39B | $46.02B | $45.68B | $45.16B | $44.36B | $44.33B | $43.71B | $2.08B | $1.90B | $1.73B | $1.46B | $1.51B | |
| Retained Earnings | $16.90B | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B | $34.47B | $34.06B | $31.16B | $33.51B | $31.61B | $32.54B | |
| Treasury Stock | $43.58B | $43.66B | $43.77B | $38.62B | $31.26B | $26.24B | $25.36B | $19.57B | $19.25B | $16.78B | $16.56B | $16.99B | |
| AOCI | $-1.52B | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B | $-1.52B | $-2.76B | $-2.29B | $-2.50B | $-2.47B | $-2.42B | |
| Stockholders' Equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B | $14.27B | $14.85B | |
| Liabilities + Equity | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B |
Przepływy pieniężne 19
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | |
| Stock-based Comp | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | |
| Deferred Tax | $-965M | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983M | $-924M | $45M | $453M | $-204M | $-347M | $-542M | |
| Amort. of Intangibles | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198M | $190M | $178M | $183M | $286M | |
| Restructuring | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | |
| Other Non-cash | $3.50B | $16.12B | $-1.16B | $-1.26B | $-663M | $10.93B | $3.37B | $76M | $2.27B | $-1.99B | $3M | $1.01B | |
| Operating Cash Flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B | $2.10B | $3.15B | |
| CapEx | $1.31B | $1.25B | $1.21B | $1.12B | $973M | $753M | $836M | $951M | $1.05B | $1.22B | $820M | $526M | |
| Investing Cash Flow | $-4.13B | $-21.35B | $-2.29B | $-1.06B | $-538M | $-10.86B | $-9.91B | $-2.00B | $-66M | $1.48B | $-1.57B | $1.22B | |
| Debt Issued | $5.74B | $12.88B | $4.46B | $5.93B | $0 | $6.95B | $26.78B | $0 | $1.49B | $0 | $1.27B | · | |
| Net Debt Issued | $-5.20B | $10.01B | $576M | $-5.50B | $-6.02B | $4.20B | $17.52B | $-5M | $264M | $-15M | $-689M | $-676M | |
| Stock Repurchased | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320M | $2.47B | $231M | · | · | |
| Net Stock Activity | $0 | $0 | $-5.16B | $-8.00B | $-6.29B | $-1.55B | $-7.30B | $-320M | $-2.47B | $-231M | · | · | |
| Dividends Paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B | |
| Financing Cash Flow | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B | $-4.08B | $-2.65B | $-3.62B | $-2.44B | |
| Net Change in Cash | $-129M | $-1.17B | $2.19B | $-4.99B | $-657M | $2.15B | $5.91B | $1.49B | $1.18B | $1.85B | $-3.19B | $1.99B | |
| Taxes Paid | $3.26B | $3.90B | $4.30B | $5.40B | $3.50B | $3.40B | $1.50B | $747M | $546M | $2.00B | $577M | $544M | |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.23B | $4.99B | $4.22B | $1.64B | $1.01B | $2.62B | |
| Levered FCF | · | · | $11.54B | $10.93B | $14.08B | $11.44B | $6.77B | $4.84B | $4.18B | $1.51B | $868M | $2.45B |
Rentowność 6
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% | 75.2% | |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | |
| Pretax Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% | 26.5% | 24.7% | 30.4% | 12.5% | 15.0% | |
| EBITDA Margin | 8.3% | 19.9% | 21.7% | 22.3% | 23.0% | 24.4% | 6.7% | 2.8% | 3.8% | 2.0% | 2.3% | 2.9% | |
| ROA | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.4% | 3.7% | 14.3% | 3.0% | 13.2% | 4.9% | 6.0% | |
| ROE | 40.5% | -39.1% | 26.5% | 18.9% | 19.0% | -20.2% | 10.5% | 38.2% | 7.2% | 29.3% | 10.8% | 13.4% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.7 | |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 | 1.2 | 1.2 | 1.3 | 1.2 | 1.1 | 0.9 | 1.1 | |
| Debt / Equity | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.0 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 2.3 | 2.9 | 1.2 | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | 0.6 | 0.4 | 0.5 | 0.5 |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | |
| Inventory Turnover | 5.3 | 5.4 | 4.3 | 4.6 | 4.8 | 3.7 | 2.9 | 5.5 | 5.0 | 4.0 | 2.8 | 2.6 | |
| Receivables Turnover | 5.2 | 5.4 | 5.3 | 5.7 | 6.1 | 6.2 | 4.7 | 5.0 | 5.1 | 5.8 | 6.6 | 8.4 |
Stopy Wzrostu 8
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.22% | 7.3% | -2.5% | -0.49% | 9.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.5% | 1.4% | 1.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 30.9% | -5.5% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 26.8% | -9.5% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 3.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.4% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 6
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Net Income TTM | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| P/E | 15.6 | -12.8 | 13.3 | 24.4 | 20.0 | -15.5 | 31.9 | 17.3 | 100.5 | 22.1 | 74.0 | 49.2 | |
| Earnings Yield | 6.4% | -7.8% | 7.5% | 4.1% | 5.0% | -6.4% | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% | 2.0% | |
| Payout Ratio | 71.5% | -54.4% | 59.1% | 73.2% | 62.8% | -45.2% | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% | 119.7% | |
| Annual Payout | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B | $3.27B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | |
| R&D Expense | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B | $2.90B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B | $1.93B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | |
| Operating Expenses | $8.89B | $8.25B | $11.03B | $9.11B | $10.50B | $8.23B | $12.17B | $10.22B | $10.91B | $23.38B | $9.80B | $8.83B | $9.37B | $8.57B | $9.55B | $9.01B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $425M | · | $280M | $282M | $288M | · | $299M | |
| Interest Income | $101M | $104M | $148M | $161M | $139M | $138M | $114M | $94M | $87M | $183M | $145M | $107M | $95M | $102M | $82M | $52M | |
| Other Non-op | $61M | $-32M | $51M | $108M | $-494M | $-339M | $-305M | $-234M | $-273M | $-81M | $371M | $258M | $116M | $413M | $217M | $140M | |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175M | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | |
| Income Tax | $770M | $561M | $384M | $919M | $460M | $509M | $99M | $461M | $-398M | $392M | $-88M | $203M | $-218M | $503M | $-166M | $601M | |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72M | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.95 | $0.75 | |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | |
| Shares (Basic) | 2,042,000,000 | 2,038,000,000 | -4,068,000,000 | 2,036,000,000 | 2,035,000,000 | 2,031,000,000 | -4,051,000,000 | 2,028,000,000 | 2,027,000,000 | 2,023,000,000 | -4,180,000,000 | 2,057,000,000 | 2,093,000,000 | 2,099,000,000 | -4,282,000,000 | 2,133,000,000 | |
| Shares (Diluted) | 2,048,000,000 | 2,047,000,000 | -4,078,000,000 | 2,039,000,000 | 2,038,000,000 | 2,040,000,000 | -4,056,000,000 | 2,031,000,000 | 2,029,000,000 | 2,023,000,000 | -4,201,000,000 | 2,064,000,000 | 2,102,000,000 | 2,113,000,000 | -4,315,000,000 | 2,148,000,000 | |
| EBITDA | · | $594M | · | · | · | $1.01B | · | · | · | $2.53B | · | · | · | $2.43B | · | · |
Bilans 29
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | · | $7.51B | $8.37B | $8.99B | · | $7.73B | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $171M | $358M | $274M | · | $1.29B | |
| Receivables | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B | $9.32B | $9.75B | $8.83B | · | $8.41B | $8.12B | $7.85B | · | $8.02B | |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B | $3.33B | $3.08B | $2.98B | · | $2.44B | $2.36B | $2.60B | · | $2.07B | |
| Other Current Assets | $4.22B | $4.60B | $4.61B | $4.95B | $5.47B | $5.53B | $5.62B | $5.62B | $5.74B | $5.57B | · | $7.21B | $6.87B | $5.16B | · | $6.08B | |
| Current Assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B | $28.07B | $26.89B | $28.67B | · | $27.63B | $28.07B | $27.09B | · | $26.80B | |
| PP&E (Net) | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B | $6.90B | $6.84B | $6.75B | · | $6.48B | $6.36B | $6.28B | · | $6.04B | |
| PP&E (Gross) | $13.34B | $13.09B | $12.84B | $12.54B | $12.68B | $12.32B | $12.09B | $11.74B | $11.93B | $11.69B | · | $11.13B | $10.83B | $10.52B | · | $10.17B | |
| Accum. Depreciation | $5.55B | $5.43B | $5.29B | $5.20B | $5.31B | $5.11B | $4.95B | $4.84B | $5.09B | $4.94B | · | $4.65B | $4.48B | $4.24B | · | $4.14B | |
| Goodwill | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | |
| Intangibles | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B | $26.96B | $29.43B | $32.76B | · | $28.95B | $31.30B | $33.57B | · | $38.18B | |
| Other Non-current Assets | $6.38B | $6.08B | $6.47B | $6.33B | $5.94B | $5.87B | $6.11B | $6.04B | $6.07B | $6.02B | · | $5.21B | $5.02B | $4.87B | · | $4.75B | |
| Total Assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B | |
| Accounts Payable | $4.16B | $4.23B | $3.58B | $4.29B | $5.43B | $4.00B | $3.60B | $3.47B | $3.75B | $3.54B | · | $2.81B | $3.07B | $3.19B | · | $2.60B | |
| Short-term Debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B | $1.08B | $3.53B | $6.19B | · | $5.47B | $3.02B | $2.75B | · | $2.13B | |
| Current Liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B | $22.64B | $23.27B | $25.82B | · | $23.46B | $20.15B | $19.09B | · | $18.93B | |
| Capital Leases | $1.73B | $1.77B | $1.83B | $1.85B | $1.55B | $1.36B | $1.37B | $1.48B | $1.44B | $1.56B | · | $1.51B | $1.34B | $1.37B | · | $845M | |
| Deferred Tax | $222M | $211M | $222M | $225M | $247M | $276M | $369M | $430M | $461M | $442M | · | $399M | $751M | $1.57B | · | $2.88B | |
| Other Non-current Liabilities | $4.34B | $4.85B | $5.04B | $5.46B | $4.94B | $4.48B | $4.47B | $4.73B | $4.99B | $6.73B | · | $6.20B | $5.90B | $6.66B | · | $6.68B | |
| Total Liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | · | $62.20B | $61.46B | $62.40B | · | $65.46B | |
| Long-term Debt | $42.86B | $44.14B | $44.83B | $48.72B | $48.95B | $49.51B | $49.43B | $49.55B | $51.95B | $52.36B | · | $37.01B | $37.07B | $37.33B | · | $38.87B | |
| Total Debt | $43.89B | $46.45B | · | $53.23B | $53.66B | $53.06B | · | $50.62B | $55.48B | $58.55B | · | $42.48B | $40.09B | $40.08B | · | $41.00B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | $292M | $292M | · | $292M | |
| Paid-in Capital | $46.50B | $46.37B | $46.39B | $46.27B | $46.13B | $46.01B | $46.02B | $45.90B | $45.77B | $45.66B | · | $44.85B | $45.30B | $45.14B | · | $44.96B | |
| Retained Earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | $16.11B | $14.91B | $16.10B | $16.10B | $15.64B | · | $28.22B | $27.45B | $26.57B | · | $24.68B | |
| Treasury Stock | $43.50B | $43.52B | $43.58B | $43.59B | $43.59B | $43.60B | $43.66B | $43.67B | $43.69B | $43.70B | · | $43.08B | $39.68B | $38.81B | · | $36.41B | |
| AOCI | $-1.29B | $-1.37B | $-1.52B | $-1.51B | $-1.55B | $-1.42B | $-1.24B | $-1.47B | $-1.46B | $-1.40B | · | $-1.29B | $-1.39B | $-1.37B | · | $-841M | |
| Stockholders' Equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | · | $29.00B | $31.97B | $31.82B | · | $32.67B | |
| Liabilities + Equity | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B |
Przepływy pieniężne 19
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $594M | $594M | $977M | $1.01B | $1.01B | $1.01B | $1.88B | $2.59B | $2.60B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | |
| Stock-based Comp | $135M | $146M | $133M | $139M | $137M | $144M | $120M | $129M | $125M | $133M | $127M | $132M | $137M | $122M | $119M | $115M | |
| Deferred Tax | $-195M | $161M | $-392M | $-359M | $-437M | $223M | $-791M | $-256M | $-331M | $-711M | $-1.33B | $-327M | $-1.09B | $-548M | $-624M | $-645M | |
| Amort. of Intangibles | $471M | $472M | $906M | $867M | $864M | $863M | $1.80B | $2.40B | $2.40B | $2.40B | $2.30B | $2.30B | $2.30B | $2.30B | $2.30B | $2.50B | |
| Restructuring | $56M | $5M | $132M | $75M | $223M | $133M | $77M | $78M | $260M | $220M | $44M | $141M | $113M | $67M | $15M | $17M | |
| Other Non-cash | · | $-2.47B | · | · | · | $-1.88B | · | · | · | $12.79B | · | · | · | $-1.29B | · | · | |
| Operating Cash Flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | |
| CapEx | $305M | $347M | $370M | $320M | $361M | $260M | $378M | $324M | $262M | $284M | $330M | $342M | $259M | $278M | $346M | $247M | |
| Investing Cash Flow | $-1.61B | $-131M | $-1.46B | $-1.70B | $-473M | $-499M | $-196M | $-219M | $-1.32B | $-19.62B | $-1.35B | $-410M | $-329M | $-210M | $1.21B | $-2.08B | |
| Debt Issued | · | · | $5.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.88B | · | · | · | · | $26M | $0 | |
| Net Debt Issued | · | $-500M | · | · | · | $0 | · | · | · | $0 | · | · | · | $-1.64B | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $4.00B | $905M | $250M | $2.42B | $701M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-250M | · | $-701M | |
| Dividends Paid | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B | $1.22B | $1.22B | $1.21B | $1.16B | $1.19B | $1.20B | $1.20B | $1.15B | $1.15B | |
| Financing Cash Flow | $-2.63B | $-1.56B | $-6.03B | $-1.49B | $-1.84B | $-993M | $-1.64B | $-3.85B | $-4.02B | $14.64B | $967M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | |
| Net Change in Cash | $-861M | $-635M | $-5.51B | $3.12B | $1.74B | $528M | $2.45B | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857M | $-623M | $-277M | $1.37B | $-3.00B | |
| Taxes Paid | · | $239M | $1.06B | $400M | $1.56B | $235M | $800M | $1.00B | $1.91B | $187M | $200M | $1.00B | $2.95B | $149M | $1.50B | $1.20B | |
| Free Cash Flow | · | $757M | · | · | · | $1.69B | · | · | · | $2.55B | · | · | · | $2.69B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.11B | · | · | · | $2.46B | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 25.6% | 23.3% | · | 18.0% | 10.7% | 21.9% | · | 10.2% | 13.8% | -100.4% | · | 17.6% | 18.5% | 20.0% | · | 14.3% | |
| Pretax Margin | 31.5% | 28.2% | · | 25.5% | 14.4% | 26.5% | · | 14.1% | 10.5% | -97.1% | · | 19.5% | 16.6% | 24.4% | · | 19.7% | |
| EBITDA Margin | · | 5.2% | · | · | · | 9.0% | · | · | · | 21.3% | · | · | · | 21.4% | · | · | |
| ROA | 3.6% | 3.0% | · | 2.3% | 1.4% | 2.6% | · | 1.3% | 1.8% | -12.3% | · | 2.0% | 2.1% | 2.3% | · | 1.5% | |
| ROE | 16.7% | 14.3% | · | 12.3% | 7.6% | 14.5% | · | 5.2% | 6.9% | -49.3% | · | 6.2% | 6.4% | 7.1% | · | 4.6% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.2 | 1.4 | 1.4 | · | 1.4 | |
| Quick Ratio | 1.0 | 0.9 | · | 0.9 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | |
| Debt / Equity | 2.0 | 2.3 | · | 2.9 | 3.1 | 3.1 | · | 3.0 | 3.3 | 3.6 | · | 1.5 | 1.3 | 1.3 | · | 1.3 | |
| LT Debt / Equity | 1.9 | 2.1 | · | 2.4 | 2.6 | 2.7 | · | 2.8 | 2.9 | 3.0 | · | 1.1 | 1.1 | 1.1 | · | 1.1 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.1 | 1.2 | 1.1 | · | 1.0 | 1.2 | 1.0 | · | 1.1 | 1.3 | 1.1 | · | 1.1 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.4 | · | 1.3 | 1.4 | 1.5 | · | 1.4 |
Wycena (TTM) 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.95B | $47.18B | · | $47.58B | $47.56B | $47.16B | · | $46.92B | $46.26B | $45.39B | · | $44.75B | $45.67B | $46.09B | · | $46.38B | |
| Net Income TTM | $9.51B | $8.64B | · | $7.18B | $6.66B | $-6.56B | · | $-7.09B | $-6.23B | $-5.65B | · | $7.87B | $7.36B | $6.57B | · | $5.85B | |
| P/E | 12.4 | 14.3 | · | 12.8 | 14.2 | -18.7 | · | -14.7 | -13.2 | -18.7 | · | 15.5 | 18.4 | 22.6 | · | 26.4 | |
| Earnings Yield | 8.1% | 7.0% | · | 7.8% | 7.1% | -5.3% | · | -6.8% | -7.6% | -5.3% | · | 6.4% | 5.4% | 4.4% | · | 3.8% | |
| Payout Ratio | · | 47.9% | · | · | · | 51.2% | · | · | · | -10.2% | · | · | · | 52.9% | · | · |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Zysk netto | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| Rozwodniony EPS | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 |
| Wskaźnik bieżący | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 |
| Wskaźnik Szybkości | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
- Czy zgłoszony megapołączony $400 miliardów AstraZeneca-Bristol Myers Squibb to pewniak — czy katastrofa czekająca na realizację?
- Bristol Myers Squibb to build $2.3 billion Houston campus
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- $400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- Bill Ackman Runs a $14 Billion Fund on Just 11 Stocks. These Are His 3 Biggest Bets Right Now.
- Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 2 793 emitenci · $58.2B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 166 (-150 vs poprzedni kw.) | 153 (+15 vs poprzedni kw.) | 990 (-41 vs poprzedni kw.) | 979 (+82 vs poprzedni kw.) | +254.4M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7 682 927 263 | 133 337 856 | 13,21% | Akcje |
| STATE STREET CORP | $5 900 803 123 | 102 408 940 | 10,15% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3 894 809 793 | 67 594 755 | 6,70% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $2 858 273 235 | 49 750 183 | 4,92% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 700 823 125 | 46 873 015 | 4,64% | Akcje |
| NORGES BANK | $2 124 256 834 | 36 866 658 | 3,65% | Akcje |
| PRIMECAP MANAGEMENT CO/CA/ | $1 436 115 120 | 24 923 900 | 2,47% | Akcje |
| AMERIPRISE FINANCIAL INC | $1 308 030 705 | 22 705 049 | 2,25% | Akcje |
| Independent Franchise Partners LLP | $1 255 703 498 | 21 792 841 | 2,16% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $938 463 230 | 16 287 109 | 1,61% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $660 776 941 | 11 467 840 | 1,14% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $585 933 423 | 10 168 924 | 1,01% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $581 119 768 | 10 085 383 | 1,00% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $494 716 447 | 8 585 846 | 0,85% | Akcje |
| BlackRock, Inc. | $492 399 085 | 8 545 628 | 0,85% | Akcje |
| FMR LLC | $451 250 223 | 7 831 486 | 0,78% | Akcje |
| TWO SIGMA ADVISERS, LP | $446 094 588 | 8 270 200 | 0,77% | Akcje |
| Robeco Institutional Asset Management B.V. | $417 435 581 | 7 244 630 | 0,72% | Akcje |
| GOLDMAN SACHS GROUP INC | $392 167 333 | 6 806 097 | 0,67% | Akcje |
| FIRST TRUST ADVISORS LP | $344 672 508 | 5 981 822 | 0,59% | Akcje |
| Capital International Investors | $340 767 005 | 5 913 752 | 0,59% | Akcje |
| Swiss National Bank | $331 822 056 | 5 758 800 | 0,57% | Akcje |
| VAN ECK ASSOCIATES CORP | $325 076 944 | 5 641 738 | 0,56% | Akcje |
| National Pension Service | $321 412 139 | 5 578 135 | 0,55% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $319 229 612 | 5 540 268 | 0,55% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $316 480 270 | 5 492 542 | 0,54% | Akcje |
| Legal & General Group Plc | $315 258 552 | 5 471 339 | 0,54% | Akcje |
| M&G PLC | $306 949 282 | 5 292 229 | 0,53% | Akcje |
| NORDEA INVESTMENT MANAGEMENT AB | $300 773 017 | 5 232 200 | 0,52% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $293 408 012 | 5 092 121 | 0,50% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $288 555 718 | 4 757 720 | 0,50% | Akcje |
| Vanguard Global Advisers, LLC | $270 856 466 | 4 700 737 | 0,47% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $266 201 519 | 4 619 950 | 0,46% | Akcje |
| California Public Employees Retirement System | $263 375 546 | 4 570 905 | 0,45% | Akcje |
| BANK OF AMERICA CORP /DE/ | $263 115 723 | 4 566 396 | 0,45% | Akcje |
| VANGUARD GROUP INC | $247 970 649 | 4 597 157 | 0,43% | Akcje |
| Caisse de depot et placement du Quebec | $243 646 343 | 4 228 503 | 0,42% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $241 222 903 | 4 186 444 | 0,41% | Akcje |
| JANE STREET GROUP, LLC | $224 896 622 | 3 903 100 | 0,39% | Opcja kupna |
| WELLINGTON MANAGEMENT GROUP LLP | $214 546 630 | 3 723 475 | 0,37% | Akcje |
| Employees Provident Fund Board | $209 755 987 | 3 640 333 | 0,36% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $201 188 241 | 3 317 201 | 0,35% | Akcje |
| CITADEL ADVISORS LLC | $194 502 072 | 3 375 600 | 0,33% | Opcja sprzedaży |
| RHUMBLINE ADVISERS | $192 874 042 | 3 347 347 | 0,33% | Akcje |
| LPL Financial LLC | $188 151 217 | 3 265 381 | 0,32% | Akcje |
| BARCLAYS PLC | $186 163 076 | 3 230 876 | 0,32% | Akcje |
| UBS Group AG | $180 243 196 | 3 128 136 | 0,31% | Akcje |
| Qube Research & Technologies Ltd | $178 273 860 | 3 093 958 | 0,31% | Akcje |
| Artemis Investment Management LLP | $175 941 518 | 3 053 480 | 0,30% | Akcje |
| SEB Asset Management AB | $165 520 833 | 2 872 632 | 0,28% | Akcje |
| Ensign Peak Advisors, Inc | $165 119 502 | 2 865 663 | 0,28% | Akcje |
| CITADEL ADVISORS LLC | $157 769 322 | 2 738 100 | 0,27% | Opcja kupna |
| JANE STREET GROUP, LLC | $152 525 902 | 2 647 100 | 0,26% | Opcja sprzedaży |
| NATIXIS | $145 152 674 | 2 519 137 | 0,25% | Akcje |
| AustralianSuper Pty Ltd | $140 209 857 | 2 433 354 | 0,24% | Akcje |
| Mirae Asset Global Investments Co., Ltd. | $138 044 440 | 2 395 773 | 0,24% | Akcje |
| Bank of New York Mellon Corp | $136 334 163 | 2 366 091 | 0,23% | Akcje |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $132 803 901 | 2 304 823 | 0,23% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $132 622 456 | 2 301 674 | 0,23% | Akcje |
| Capital World Investors | $129 313 224 | 2 244 242 | 0,22% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $129 300 432 | 2 244 020 | 0,22% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $125 419 207 | 2 176 661 | 0,22% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $123 353 032 | 2 140 802 | 0,21% | Akcje |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $122 879 893 | 2 132 591 | 0,21% | Akcje |
| PFA Pension, Forsikringsaktieselskab | $121 829 832 | 2 114 367 | 0,21% | Akcje |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $120 528 714 | 2 234 496 | 0,21% | Akcje |
| MACKENZIE FINANCIAL CORP | $118 944 044 | 2 064 284 | 0,20% | Akcje |
| Pictet Asset Management Holding SA | $116 783 155 | 2 026 687 | 0,20% | Akcje |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $116 161 574 | 2 015 994 | 0,20% | Akcje |
| TD Asset Management Inc | $115 669 154 | 2 007 448 | 0,20% | Akcje |
| SUSQUEHANNA ADVISORS GROUP, INC. | $115 240 000 | 2 000 000 | 0,20% | Opcja kupna |
| MACQUARIE GROUP LTD | $111 978 478 | 1 943 396 | 0,19% | Akcje |
| Vinva Investment Management Ltd | $109 557 913 | 1 870 866 | 0,19% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $108 509 833 | 1 883 218 | 0,19% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $106 751 521 | 1 760 124 | 0,18% | Akcje |
| LMR Partners LLP | $106 066 896 | 1 840 800 | 0,18% | Opcja sprzedaży |
| AVIVA PLC | $103 620 639 | 1 798 345 | 0,18% | Akcje |
| PRUDENTIAL FINANCIAL INC | $103 202 606 | 1 791 090 | 0,18% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $102 378 000 | 1 776 782 | 0,18% | Akcje |
| STOREBRAND ASSET MANAGEMENT AS | $101 037 131 | 1 753 508 | 0,17% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $100 790 172 | 1 749 222 | 0,17% | Akcje |
| BANK OF NOVA SCOTIA | $99 453 647 | 1 726 026 | 0,17% | Akcje |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $98 875 920 | 1 716 000 | 0,17% | Akcje |
| KLP KAPITALFORVALTNING AS | $94 673 002 | 1 643 058 | 0,16% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $90 576 678 | 1 567 009 | 0,16% | Akcje |
| BANK OF MONTREAL /CAN/ | $89 684 378 | 1 556 480 | 0,15% | Akcje |
| Douglas Lane & Associates, LLC | $89 667 305 | 1 556 184 | 0,15% | Akcje |
| PNC Financial Services Group, Inc. | $89 112 096 | 1 546 548 | 0,15% | Akcje |
| Walleye Trading LLC | $88 014 550 | 1 527 500 | 0,15% | Opcja kupna |
| Korea Investment CORP | $86 518 389 | 1 501 534 | 0,15% | Akcje |
| APG Asset Management N.V. | $85 242 422 | 1 691 386 | 0,15% | Akcje |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $85 175 958 | 1 478 236 | 0,15% | Akcje |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $84 205 059 | 1 764 695 | 0,14% | Akcje |
| Mariner, LLC | $83 309 670 | 1 445 809 | 0,14% | Akcje |
| Retirement Systems of Alabama | $80 928 212 | 1 404 516 | 0,14% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $80 695 542 | 1 400 478 | 0,14% | Akcje |
| Nuveen Asset Management, LLC | $76 733 142 | 1 356 668 | 0,13% | Akcje |
| CWM, LLC | $76 220 909 | 1 256 734 | 0,13% | Akcje |
| Eurizon Capital SGR S.p.A. | $70 986 984 | 1 230 296 | 0,12% | Akcje |
| Aberdeen Group plc | $70 798 674 | 1 228 717 | 0,12% | Akcje |
Insiderzy spółki 102 insiderów · 65 dyrektorzy generalni · 37 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 13 czerwca 2025 G | 125 439 | 0 | 0 | $0 |
| Peter R Dolan | Former CEO | 8 września 2006 F | 571 673 | 0 | 0 | $0 |
| David V Elkins | EVP, Chief Financial Officer | 2 września 2025 S | 167 379 | 0 | 1 | $-2 650 480 |
| Jean-Marc Huet | EVP & CFO | 30 kwietnia 2009 P | 25 000 | 0 | 0 | $0 |
| Benjamin Hickey | President, RayzeBio Org. | 9 maja 2025 S | 0 | 0 | 0 | $0 |
| Lynelle Hoch | President, Cell Therapy Org. | 10 marca 2025 A | 4 711 | 0 | 0 | $0 |
| James B D Palmer DR | CSO & President, PRI | 2 marca 2004 A | 178 889 | 0 | 0 | $0 |
| Dean J Mitchell | President, U.S. Primary Care | 10 września 2003 A | 60 000 | 0 | 0 | $0 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 1 sierpnia 2026 M | 24 997 | 0 | 0 | $0 |
| Cari Gallman | EVP, General Counsel | 1 sierpnia 2026 M | 13 649 | 0 | 0 | $0 |
| Bartie Wendy Short | EVP, Corporate Affairs | 3 czerwca 2026 F | 12 081 | 0 | 0 | $0 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 1 lipca 2025 A | — | 0 | 0 | $0 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 1 maja 2025 J | 12 439 | 0 | 0 | $0 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 25 kwietnia 2025 P | 83 513 | 0 | 0 | $0 |
| Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 1 kwietnia 2025 M | 13 797 | 0 | 0 | $0 |
| Phil M Holzer | SVP and Controller | 10 marca 2025 A | 14 967 | 0 | 0 | $0 |
| Ahn Amanda Poole | EVP, Chief People Officer | 10 marca 2025 A | 5 196 | 0 | 0 | $0 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 10 marca 2025 A | 16 102 | 0 | 0 | $0 |
| Robert M Plenge | EVP, Chief Research Officer | 10 marca 2025 A | 15 839 | 0 | 0 | $0 |
| Sandra Leung | EVP, General Counsel | 10 marca 2025 A | 364 296 | 0 | 0 | $0 |
| Giovanni Caforio | Executive Chair of the Board | 10 marca 2024 M | 432 266 | 0 | 0 | $0 |
| Ann Powell Judge | EVP, Chief Human Resources | 24 sierpnia 2023 S | 27 868 | 0 | 0 | $0 |
| Michelle Weese | EVP, Corporate Affairs | 1 lipca 2023 M | 3 453 | 0 | 0 | $0 |
| Rupert Vessey | EVP & President, Research | 3 maja 2023 S | 47 751 | 0 | 0 | $0 |
| Sharon Greenlees | SVP & Controller | 2 maja 2023 M | 609 | 0 | 0 | $0 |
| Elizabeth Mily | EVP, Strategy & BD | 1 kwietnia 2023 M | 34 734 | 0 | 0 | $0 |
| Karen Murphy Santiago | SVP & Controller | 14 marca 2022 S | 16 704 | 0 | 0 | $0 |
| Paul Von Autenried | EVP, Chief Information Officer | 24 listopada 2021 S | 63 536 | 0 | 0 | $0 |
| Adam Dubow | SVP,ChiefCompliance&EthicsOff. | 30 lipca 2021 S | 13 777 | 0 | 0 | $0 |
| Joseph Eid | SVP,Head Glob. Medical Affairs | 3 czerwca 2021 M | 9 485 | 0 | 0 | $0 |
| Louis S Schmukler | EVP,Pres.,Glob.Prod. & Supply | 10 maja 2021 S | 31 956 | 0 | 0 | $0 |
| Kathryn Metcalfe | EVP, Corporate Affairs | 10 marca 2020 A | — | 0 | 0 | $0 |
| John E Elicker | EVP, Investor Relations | 10 marca 2020 M | 70 946 | 0 | 0 | $0 |
| Charles A Bancroft | EVP, Head of Integration | 10 marca 2020 M | 137 534 | 0 | 0 | $0 |
| Paul Biondi | SVP, Head of Strategy & BD | 2 października 2019 M | 6 214 | 0 | 0 | $0 |
| Thomas J. Lynch Jr. | EVP & Chief Scientific Officer | 3 kwietnia 2019 M | 22 223 | 0 | 0 | $0 |
| Murdo Gordon | EVP, Chief Commercial Officer | 1 sierpnia 2018 M | 49 424 | 0 | 0 | $0 |
| Joseph C Caldarella | SVP & Controller | 6 września 2017 S | 46 297 | 0 | 0 | $0 |
| Anne Nielsen | Chief Compliance & Ethics Off | 3 września 2017 M | 37 974 | 0 | 0 | $0 |
| Emmanuel Blin | SVP, Chief Strategy Officer | 10 marca 2017 A | 20 138 | 0 | 0 | $0 |
| Francis M Cuss | EVP & CSO | 10 marca 2017 M | 321 906 | 0 | 0 | $0 |
| Samuel J Moed | SVP, Strat Plan & Analysis | 13 marca 2015 S | 31 015 | 0 | 0 | $0 |
| Brian Daniels | SVP Global Dev & Med Affairs | 1 lipca 2014 M | 94 374 | 0 | 0 | $0 |
| Frances K Heller | SVP, Business Development | 10 marca 2014 A | 4 174 | 0 | 0 | $0 |
| Elliot Sigal | EVP, CSO & President R&D | 3 czerwca 2013 M | 148 221 | 0 | 0 | $0 |
| Beatrice J Cazala | EVP Commercial Operations | 31 maja 2013 S | 173 375 | 0 | 0 | $0 |
| John E Celentano | SVP HR Public Affairs & Philan | 6 marca 2012 M | 142 142 | 0 | 0 | $0 |
| Jeremy M Levin | SVP Strat Transactions | 1 października 2011 M | 43 689 | 0 | 0 | $0 |
| De Notaristefani Carlo | Pres Tech Ops & Supp Fnctns | 14 czerwca 2011 M | 7 578 | 0 | 0 | $0 |
| Anthony C Hooper | SVP ComOps Pres USJap Int | 13 maja 2011 M | 203 170 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 11 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION ×3 zgłoszenia | 16 lipca 2020 | — | Pierwotne zgłoszenie | — | SEC |
| Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP | 27 lutego 2019 | — | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| S.S. OR ×3 zgłoszenia | 23 grudnia 2009 | — | Pierwotne zgłoszenie | — | SEC |
| Medarex, Inc. S.S. OR, S.S. OR | 25 listopada 2009 | — | Pierwotne zgłoszenie | — | SEC |
| Identification Nos. of Above Persons (entities only) Bristol-Myers Squibb Company ×2 zgłoszenia | 27 lutego 2009 | — | Pierwotne zgłoszenie | — | SEC |
| Bristol -Myers Squibb Company, Bristol -Myers Squibb Biologics Company ×3 zgłoszenia | 8 października 2008 | — | Pierwotne zgłoszenie | — | SEC |
| Bristol-Myers Squibb Company I.R.S. Employer Identification Number 22-079-0350 ×3 zgłoszenia | 6 czerwca 2003 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 16 kwietnia 2003 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 3 lutego 2003 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 6 marca 2002 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 6 lutego 2002 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 279 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| RDIV · Invesco Exchange-Traded Fund Trust … | 5,25% | 1 129 070 SH | 8 sierpnia 2026 | Dziennie |
| ROPE · EA Series Trust | 4,97% | 7 379 NS | 29 maja 2026 | N-PORT |
| IHE · iShares Trust | 4,70% | 1 186 434 SH | 8 sierpnia 2026 | Dziennie |
| CAMX · ADVISORS' INNER CIRCLE FUND | 4,10% | 44 768 NS | 30 kwietnia 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,50% | 6 427 NS | 30 kwietnia 2026 | N-PORT |
| CANC · Tema ETF Trust | 3,30% | 101 680 NS | 31 maja 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3,21% | 2 332 NS | 30 kwietnia 2026 | N-PORT |
| AGNG · Global X Funds | 2,98% | 42 594 NS | 31 maja 2026 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 2,93% | 48 641 121 NS | 31 maja 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,83% | 221 806 SH | 8 sierpnia 2026 | Dziennie |
| ABFL · Abacus FCF ETF Trust | 2,76% | 226 688 NS | 30 kwietnia 2026 | N-PORT |
| HDV · iShares Trust | 2,65% | 6 116 696 SH | 8 sierpnia 2026 | Dziennie |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 234 394 NS | 31 maja 2026 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 210 030 NS | 31 maja 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2,45% | 148 728 NS | 31 maja 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,18% | 1 612 NS | 30 kwietnia 2026 | N-PORT |
| IYH · iShares Trust | 2,13% | 1 222 783 SH | 8 sierpnia 2026 | Dziennie |
| HRTS · Tema ETF Trust | 2,09% | 18 939 NS | 31 maja 2026 | N-PORT |
| FDIV · EA Series Trust | 2,07% | 24 896 NS | 30 kwietnia 2026 | N-PORT |
| SPHD · Invesco Exchange-Traded Fund Trust … | 2,06% | 1 090 699 SH | 8 sierpnia 2026 | Dziennie |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,06% | 38 747 SH | 8 sierpnia 2026 | Dziennie |
| GCOW · Pacer Funds Trust | 2,03% | 1 123 894 NS | 30 kwietnia 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 2,03% | 6 082 360 NS | 30 kwietnia 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 2,03% | 15 628 NS | 30 kwietnia 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,02% | 30 055 NS | 30 kwietnia 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,99% | 938 456 NS | 30 kwietnia 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 1,98% | 1 422 NS | 30 kwietnia 2026 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 1,91% | 31 120 SH | 8 sierpnia 2026 | Dziennie |
| SDOG · ALPS ETF Trust | 1,83% | 441 820 NS | 31 maja 2026 | N-PORT |
| RFDA · ALPS ETF Trust | 1,82% | 27 812 NS | 31 maja 2026 | N-PORT |
| PEY · Invesco Exchange-Traded Fund Trust | 1,82% | 328 134 SH | 8 sierpnia 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 1,78% | 40 606 NS | 30 kwietnia 2026 | N-PORT |
| FLOW · Global X Funds | 1,78% | 8 912 NS | 31 maja 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,76% | 213 243 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 1,73% | 6 137 665 SH | 8 sierpnia 2026 | Dziennie |
| RXL · ProShares Trust | 1,68% | 21 228 NS | 31 maja 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,66% | 26 358 NS | 31 maja 2026 | N-PORT |
| IXJ · iShares Trust | 1,66% | 1 073 117 SH | 8 sierpnia 2026 | Dziennie |
| VMAX · Lattice Strategies Trust | 1,65% | 12 671 NS | 30 kwietnia 2026 | N-PORT |
| NULV · Nushares ETF Trust | 1,57% | 539 514 NS | 30 kwietnia 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,54% | 13 556 NS | 30 kwietnia 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,54% | 11 473 NS | 30 kwietnia 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,47% | 408 226 SH | 8 sierpnia 2026 | Dziennie |
| COWG · Pacer Funds Trust | 1,47% | 526 151 NS | 30 kwietnia 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1,46% | 68 134 NS | 30 kwietnia 2026 | N-PORT |
| TMFE · RBB Fund, Inc. | 1,45% | 21 473 NS | 31 maja 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,43% | 64 178 NS | 30 kwietnia 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,35% | 2 876 NS | 30 kwietnia 2026 | N-PORT |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 1,32% | 1 547 107 NS | 30 kwietnia 2026 | N-PORT |
| JDIV · J.P. Morgan Exchange-Traded Fund Tr… | 1,31% | 2 430 NS | 30 kwietnia 2026 | N-PORT |